Details of the Drug Therapeutic Target (DTT)

General Information of Drug Therapeutic Target (DTT) (ID: TTV3CFI)

DTT Name	MHC class I NK cell receptor 2DS2 (CD158j)
Synonyms	p58 natural killer cell receptor clone CL-49; p58 NK receptor CL-49; Natural killer-associated transcript 5; NKAT5; NKAT-5; NK receptor 183 ActI; MHC class I NK cell receptor; Killer cell immunoglobulin-like receptor 2DS2; CD158J; CD158 antigen-like family member J
Gene Name	KIR2DS2
DTT Type	Clinical trial target	[1]
BioChemical Class	Immunoglobulin
UniProt ID	KI2S2_HUMAN
TTD ID	T77515
3D Structure	Download 2D Sequence (FASTA) Download 3D Structure (PDB) Download
Sequence	MSLMVVSMACVGFFLLQGAWPHEGVHRKPSLLAHPGPLVKSEETVILQCWSDVRFEHFLL HREGKYKDTLHLIGEHHDGVSKANFSIGPMMQDLAGTYRCYGSVTHSPYQLSAPSDPLDI VITGLYEKPSLSAQPGPTVLAGESVTLSCSSRSSYDMYHLSREGEAHERRFSAGPKVNGT FQADFPLGPATHGGTYRCFGSFRDSPYEWSNSSDPLLVSVTGNPSNSWPSPTEPSSKTGN PRHLHVLIGTSVVKIPFTILLFFLLHRWCSNKKNAAVMDQEPAGNRTVNSEDSDEQDHQE VSYA
Function	Receptor on natural killer (NK) cells for HLA-C alleles. Does not inhibit the activity of NK cells.
KEGG Pathway	Antigen processing and presentation (hsa04612 ) Natural killer cell mediated cytotoxicity (hsa04650 )
Reactome Pathway	DAP12 interactions (R-HSA-2172127 ) Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell (R-HSA-198933 )

Molecular Interaction Atlas (MIA) of This DTT

Molecular Interaction Atlas (MIA)

Jump to Detail Molecular Interaction Atlas of This DTT

1 Clinical Trial Drug(s) Targeting This DTT

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
IPH-2101	DMDUVCZ	Multiple myeloma	2A83	Phase 2	[1]
------------------------------------------------------------------------------------

References

1	Daratumumab-mediated lysis of primary multiple myeloma cells is enhanced in combination with the human anti-KIR antibody IPH2102 and lenalidomide. Haematologica. 2015 Feb;100(2):263-8.